Method for treating blood, blood products and organs

1. A method for treating blood, a blood product and/or an organ in vitro or ex vivo, wherein the method comprises removing the blood, blood product and/or organ from the human or animal body and removing and/or detoxifying amyloid-beta oligomers from the removed blood, blood product and/or organ, and wherein the method comprises contacting the blood, blood product and/or organ with the peptide of formula rprtrlhthrnrrprtrlhthrnr (D3D3, SEQ ID NO:13).

2. The method of claim 1 , wherein the method further comprises examining the blood, blood product and/or organ for the presence of amyloid-beta oligomers prior to removing the blood, blood product and/or organ from the human or animal body.

3. The method of claim 1 , wherein molecules of the peptide of SEQ ID NO:13 are arranged as capture molecules on a support, via which a sample containing the blood, blood product and/or organ is passed.

4. The method of claim 3 , wherein the capture molecules are fixed onto beads.

5. The method of claim 3 , wherein the capture molecules are immobilized on nanomagnets.

6. The method of claim 3 , wherein the capture molecules are arranged in a dialysis system.

7. The method of claim 3 , wherein the support for the capture molecules is made of a biocompatible material.

8. The method of claim 3 , wherein the support for the capture molecules is selected from one or more of membranes, filters, filter sponges, beads, rods, cords, column, and hollow fibers.

9. The method of claim 1 , wherein a kit is used for a selective quantification of amyloid-beta aggregates and/or for treating (in vitro) blood, a blood product and/or an organ, the kit comprising one or more of:

a substrate made of glass which is coated with a hydrophobic material;

a standard;

a capture molecule;

a probe;

a substrate with capture molecule;

one or more solutions; and

a buffer.

10. The method of claim 1 , wherein molecules of the peptide of SEQ ID NO:13 are passed as capture molecules ex vivo over and/or through an organ.

11. The method of claim 1 , wherein the method comprises removing amyloid-beta oligomers from blood, a blood product and/or an organ.

12. The method of claim 11 , wherein Alzheimer's disease is treated.

13. The method of claim 1 , wherein the method comprises detoxifying amyloid-beta oligomers present in blood, a blood product and/or an organ.

14. The method of claim 13 , wherein Alzheimer's disease is treated.